Federal Register #2026-10674

FDA Renews Psychopharmacologic Drugs Advisory Committee for Two Years

This notice announces the renewal of the Psychopharmacologic Drugs Advisory Committee at the Food and Drug Administration (FDA): - Government Buyer: - Department of Health and Human Services (HHS) - Food and Drug Administration (FDA) - Purpose: - Renewal of the Psychopharmacologic Drugs Advisory Committee for an additional two years - Committee provides expert advice to the FDA Commissioner on the safety and effectiveness of psychiatric drug products - Committee Details: - At least six voting members with expertise in psychopharmacology, psychiatry, epidemiology, statistics, and related fields - Supports FDA's regulatory mission for psychiatric drug products - No procurement of products or services is involved - No OEMs, vendors, part numbers, or purchase quantities are mentioned - Location: - Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver Spring, MD 20993-0002

Description

The Food and Drug Administration (FDA) is announcing the renewal of the Psychopharmacologic Drugs Advisory Committee by the Commissioner of Food and Drugs. The committee provides expert advice on the safety and effectiveness of marketed and investigational human drug products for use in psychiatry and related specialties. The renewal extends the committee's charter until June 4, 2028. The committee consists of at least six voting members with expertise in psychopharmacology, psychiatry, epidemiology, statistics, and related fields, and supports FDA's regulatory mission.

View original listing